nodes	percent_of_prediction	percent_of_DWPC	metapath
Imatinib—ORM1—bile—bile duct cancer	0.0438	0.112	CbGeAlD
Imatinib—CA9—gall bladder—bile duct cancer	0.0207	0.0532	CbGeAlD
Imatinib—DDR1—pancreas—bile duct cancer	0.0169	0.0434	CbGeAlD
Imatinib—PDGFRA—gall bladder—bile duct cancer	0.0166	0.0426	CbGeAlD
Imatinib—KIT—gall bladder—bile duct cancer	0.0133	0.0341	CbGeAlD
Imatinib—PDGFRB—gall bladder—bile duct cancer	0.013	0.0333	CbGeAlD
Imatinib—ORM1—gall bladder—bile duct cancer	0.0122	0.0312	CbGeAlD
Imatinib—DDR1—liver—bile duct cancer	0.0108	0.0276	CbGeAlD
Imatinib—ALB—gall bladder—bile duct cancer	0.0107	0.0274	CbGeAlD
Imatinib—PIP4K2C—pancreas—bile duct cancer	0.0104	0.0268	CbGeAlD
Imatinib—ABCA3—lymph node—bile duct cancer	0.00895	0.023	CbGeAlD
Imatinib—DDR1—lymph node—bile duct cancer	0.00826	0.0212	CbGeAlD
Imatinib—CA2—gall bladder—bile duct cancer	0.00787	0.0202	CbGeAlD
Imatinib—NQO2—pancreas—bile duct cancer	0.00767	0.0197	CbGeAlD
Imatinib—ABL2—liver—bile duct cancer	0.00702	0.018	CbGeAlD
Imatinib—PIP4K2C—liver—bile duct cancer	0.00665	0.0171	CbGeAlD
Imatinib—CA3—liver—bile duct cancer	0.00635	0.0163	CbGeAlD
Imatinib—KIT—pancreas—bile duct cancer	0.00612	0.0157	CbGeAlD
Imatinib—PDGFRB—pancreas—bile duct cancer	0.00597	0.0153	CbGeAlD
Imatinib—LCK—liver—bile duct cancer	0.0059	0.0151	CbGeAlD
Imatinib—CA14—liver—bile duct cancer	0.00576	0.0148	CbGeAlD
Imatinib—CYP3A7—liver—bile duct cancer	0.00564	0.0145	CbGeAlD
Imatinib—CA1—pancreas—bile duct cancer	0.00559	0.0144	CbGeAlD
Imatinib—ABL2—lymph node—bile duct cancer	0.00539	0.0138	CbGeAlD
Imatinib—ABL1—pancreas—bile duct cancer	0.00533	0.0137	CbGeAlD
Imatinib—PIP4K2C—lymph node—bile duct cancer	0.0051	0.0131	CbGeAlD
Imatinib—NQO2—liver—bile duct cancer	0.00488	0.0125	CbGeAlD
Imatinib—PDGFRA—liver—bile duct cancer	0.00487	0.0125	CbGeAlD
Imatinib—CA3—lymph node—bile duct cancer	0.00487	0.0125	CbGeAlD
Imatinib—CYP3A7-CYP3A51P—liver—bile duct cancer	0.00479	0.0123	CbGeAlD
Imatinib—LCK—lymph node—bile duct cancer	0.00452	0.0116	CbGeAlD
Imatinib—CSF1R—liver—bile duct cancer	0.00429	0.011	CbGeAlD
Imatinib—SLC47A1—liver—bile duct cancer	0.00391	0.01	CbGeAlD
Imatinib—KIT—liver—bile duct cancer	0.00389	0.00999	CbGeAlD
Imatinib—PDGFRB—liver—bile duct cancer	0.0038	0.00976	CbGeAlD
Imatinib—NQO2—lymph node—bile duct cancer	0.00374	0.0096	CbGeAlD
Imatinib—PDGFRA—lymph node—bile duct cancer	0.00373	0.00958	CbGeAlD
Imatinib—CA2—pancreas—bile duct cancer	0.00363	0.00931	CbGeAlD
Imatinib—ORM1—liver—bile duct cancer	0.00357	0.00915	CbGeAlD
Imatinib—CA1—liver—bile duct cancer	0.00356	0.00914	CbGeAlD
Imatinib—ABL1—liver—bile duct cancer	0.00339	0.0087	CbGeAlD
Imatinib—CSF1R—lymph node—bile duct cancer	0.00329	0.00843	CbGeAlD
Imatinib—SLC22A1—liver—bile duct cancer	0.00327	0.00838	CbGeAlD
Imatinib—ALB—liver—bile duct cancer	0.00313	0.00802	CbGeAlD
Imatinib—CYP3A5—pancreas—bile duct cancer	0.00312	0.008	CbGeAlD
Imatinib—SLC47A1—lymph node—bile duct cancer	0.003	0.0077	CbGeAlD
Imatinib—KIT—lymph node—bile duct cancer	0.00298	0.00766	CbGeAlD
Imatinib—PDGFRB—lymph node—bile duct cancer	0.00291	0.00748	CbGeAlD
Imatinib—ORM1—lymph node—bile duct cancer	0.00273	0.00702	CbGeAlD
Imatinib—CA1—lymph node—bile duct cancer	0.00273	0.007	CbGeAlD
Imatinib—ABL1—lymph node—bile duct cancer	0.0026	0.00667	CbGeAlD
Imatinib—CYP2C19—liver—bile duct cancer	0.00252	0.00646	CbGeAlD
Imatinib—ALB—lymph node—bile duct cancer	0.0024	0.00615	CbGeAlD
Imatinib—CA2—liver—bile duct cancer	0.00231	0.00592	CbGeAlD
Imatinib—ABCG2—liver—bile duct cancer	0.00214	0.00548	CbGeAlD
Imatinib—CYP1A2—liver—bile duct cancer	0.00206	0.00528	CbGeAlD
Imatinib—CYP3A5—liver—bile duct cancer	0.00198	0.00509	CbGeAlD
Imatinib—CYP2C9—liver—bile duct cancer	0.00195	0.00501	CbGeAlD
Imatinib—CA2—lymph node—bile duct cancer	0.00177	0.00454	CbGeAlD
Imatinib—ABCB1—pancreas—bile duct cancer	0.00166	0.00425	CbGeAlD
Imatinib—ABCG2—lymph node—bile duct cancer	0.00164	0.0042	CbGeAlD
Imatinib—CYP3A4—liver—bile duct cancer	0.00149	0.00382	CbGeAlD
Imatinib—CYP2D6—liver—bile duct cancer	0.00146	0.00376	CbGeAlD
Imatinib—PTGS1—lymph node—bile duct cancer	0.00137	0.00351	CbGeAlD
Imatinib—ABCB1—liver—bile duct cancer	0.00105	0.0027	CbGeAlD
Imatinib—ABCB1—lymph node—bile duct cancer	0.000808	0.00207	CbGeAlD
Imatinib—LCK—Immune System—HGF—bile duct cancer	0.000124	0.000204	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—GNAS—bile duct cancer	0.000123	0.000202	CbGpPWpGaD
Imatinib—CA2—Metabolism—PTGS2—bile duct cancer	0.000123	0.000202	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—ERBB2—bile duct cancer	0.000123	0.000202	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—IDH2—bile duct cancer	0.000123	0.000201	CbGpPWpGaD
Imatinib—LCK—Cytokine Signaling in Immune system—HRAS—bile duct cancer	0.000122	0.0002	CbGpPWpGaD
Imatinib—PDGFRA—Disease—NOS2—bile duct cancer	0.000122	0.000199	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—TGFBR2—bile duct cancer	0.000121	0.000198	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—SMAD4—bile duct cancer	0.000121	0.000198	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—SLC5A5—bile duct cancer	0.000121	0.000198	CbGpPWpGaD
Imatinib—LCK—Signaling by NGF—HRAS—bile duct cancer	0.00012	0.000197	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—IDH2—bile duct cancer	0.00012	0.000196	CbGpPWpGaD
Imatinib—KIT—Adaptive Immune System—EGFR—bile duct cancer	0.00012	0.000196	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—TGFB1—bile duct cancer	0.00012	0.000196	CbGpPWpGaD
Imatinib—LCK—Disease—SMAD4—bile duct cancer	0.000118	0.000194	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—ERBB2—bile duct cancer	0.000118	0.000194	CbGpPWpGaD
Imatinib—CA1—Metabolism—PTGS2—bile duct cancer	0.000118	0.000193	CbGpPWpGaD
Imatinib—PDGFRA—Innate Immune System—EGFR—bile duct cancer	0.000118	0.000193	CbGpPWpGaD
Imatinib—KIT—Innate Immune System—KRAS—bile duct cancer	0.000118	0.000193	CbGpPWpGaD
Imatinib—ALB—Metabolism—IDH1—bile duct cancer	0.000118	0.000193	CbGpPWpGaD
Imatinib—SLC22A2—Neuronal System—HRAS—bile duct cancer	0.000117	0.000192	CbGpPWpGaD
Imatinib—ABL1—Hemostasis—TGFB1—bile duct cancer	0.000117	0.000192	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—EGFR—bile duct cancer	0.000117	0.000192	CbGpPWpGaD
Imatinib—LCK—Cytokine Signaling in Immune system—IL6—bile duct cancer	0.000117	0.000191	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—GNAS—bile duct cancer	0.000117	0.000191	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—NRAS—bile duct cancer	0.000117	0.000191	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—SLC5A5—bile duct cancer	0.000116	0.00019	CbGpPWpGaD
Imatinib—LCK—Signaling by NGF—IL6—bile duct cancer	0.000115	0.000188	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—SMAD4—bile duct cancer	0.000114	0.000188	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—NRAS—bile duct cancer	0.000114	0.000186	CbGpPWpGaD
Imatinib—PDGFRA—Adaptive Immune System—EGFR—bile duct cancer	0.000113	0.000186	CbGpPWpGaD
Imatinib—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—bile duct cancer	0.000113	0.000185	CbGpPWpGaD
Imatinib—KIT—Adaptive Immune System—KRAS—bile duct cancer	0.000113	0.000185	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—IDH2—bile duct cancer	0.000113	0.000185	CbGpPWpGaD
Imatinib—ABCB1—Transmembrane transport of small molecules—GNAS—bile duct cancer	0.000113	0.000185	CbGpPWpGaD
Imatinib—ALB—Platelet activation, signaling and aggregation—TGFB1—bile duct cancer	0.000112	0.000184	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—NRAS—bile duct cancer	0.000112	0.000183	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—IDH2—bile duct cancer	0.000112	0.000183	CbGpPWpGaD
Imatinib—PDGFRA—Innate Immune System—KRAS—bile duct cancer	0.000111	0.000183	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—KRAS—bile duct cancer	0.000111	0.000181	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—bile duct cancer	0.00011	0.000181	CbGpPWpGaD
Imatinib—PDGFRB—Disease—NOS2—bile duct cancer	0.00011	0.00018	CbGpPWpGaD
Imatinib—SLC22A1—Neuronal System—HRAS—bile duct cancer	0.000109	0.000179	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—TGFBR2—bile duct cancer	0.000109	0.000178	CbGpPWpGaD
Imatinib—ABL1—Hemostasis—KRAS—bile duct cancer	0.000109	0.000178	CbGpPWpGaD
Imatinib—ALB—Hemostasis—NOS2—bile duct cancer	0.000109	0.000178	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bile duct cancer	0.000108	0.000177	CbGpPWpGaD
Imatinib—PDGFRA—Adaptive Immune System—KRAS—bile duct cancer	0.000107	0.000175	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—EGFR—bile duct cancer	0.000106	0.000174	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—IDH1—bile duct cancer	0.000106	0.000173	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—GNAS—bile duct cancer	0.000105	0.000172	CbGpPWpGaD
Imatinib—KIT—Immune System—ERBB2—bile duct cancer	0.000105	0.000172	CbGpPWpGaD
Imatinib—LCK—Hemostasis—NRAS—bile duct cancer	0.000104	0.00017	CbGpPWpGaD
Imatinib—CA9—Metabolism—PTGS2—bile duct cancer	0.000104	0.00017	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—EGFR—bile duct cancer	0.000104	0.00017	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—SMAD4—bile duct cancer	0.000103	0.000169	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—IDH1—bile duct cancer	0.000103	0.000169	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—bile duct cancer	0.000102	0.000167	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—EGFR—bile duct cancer	0.000102	0.000167	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—KRAS—bile duct cancer	0.0001	0.000164	CbGpPWpGaD
Imatinib—KIT—Innate Immune System—HRAS—bile duct cancer	0.0001	0.000164	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—ERBB2—bile duct cancer	9.91e-05	0.000162	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—KRAS—bile duct cancer	9.78e-05	0.00016	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—GNAS—bile duct cancer	9.77e-05	0.00016	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—IDH1—bile duct cancer	9.71e-05	0.000159	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—GNAS—bile duct cancer	9.68e-05	0.000159	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—GNAS—bile duct cancer	9.67e-05	0.000158	CbGpPWpGaD
Imatinib—KIT—Disease—ERBB2—bile duct cancer	9.66e-05	0.000158	CbGpPWpGaD
Imatinib—LCK—Hemostasis—TGFB1—bile duct cancer	9.66e-05	0.000158	CbGpPWpGaD
Imatinib—ABL1—Hemostasis—TP53—bile duct cancer	9.66e-05	0.000158	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—KRAS—bile duct cancer	9.64e-05	0.000158	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—IDH1—bile duct cancer	9.63e-05	0.000158	CbGpPWpGaD
Imatinib—KIT—Adaptive Immune System—HRAS—bile duct cancer	9.61e-05	0.000157	CbGpPWpGaD
Imatinib—KIT—Innate Immune System—IL6—bile duct cancer	9.57e-05	0.000157	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—IDH2—bile duct cancer	9.57e-05	0.000157	CbGpPWpGaD
Imatinib—PDGFRA—Innate Immune System—HRAS—bile duct cancer	9.47e-05	0.000155	CbGpPWpGaD
Imatinib—KIT—Disease—PTGS2—bile duct cancer	9.45e-05	0.000155	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—HRAS—bile duct cancer	9.41e-05	0.000154	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—GNAS—bile duct cancer	9.39e-05	0.000154	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—NRAS—bile duct cancer	9.36e-05	0.000153	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—ERBB2—bile duct cancer	9.24e-05	0.000151	CbGpPWpGaD
Imatinib—ABL1—Hemostasis—HRAS—bile duct cancer	9.23e-05	0.000151	CbGpPWpGaD
Imatinib—PDGFRA—Disease—ERBB2—bile duct cancer	9.15e-05	0.00015	CbGpPWpGaD
Imatinib—PDGFRA—Adaptive Immune System—HRAS—bile duct cancer	9.09e-05	0.000149	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bile duct cancer	9.08e-05	0.000149	CbGpPWpGaD
Imatinib—PDGFRA—Innate Immune System—IL6—bile duct cancer	9.06e-05	0.000148	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—GNAS—bile duct cancer	9.01e-05	0.000148	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—IL6—bile duct cancer	9.01e-05	0.000148	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—SLC5A5—bile duct cancer	9.01e-05	0.000148	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—NRAS—bile duct cancer	8.99e-05	0.000147	CbGpPWpGaD
Imatinib—LCK—Hemostasis—KRAS—bile duct cancer	8.95e-05	0.000147	CbGpPWpGaD
Imatinib—PDGFRA—Disease—PTGS2—bile duct cancer	8.95e-05	0.000147	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—ERBB2—bile duct cancer	8.93e-05	0.000146	CbGpPWpGaD
Imatinib—LCK—Disease—NOS2—bile duct cancer	8.8e-05	0.000144	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—TGFBR2—bile duct cancer	8.74e-05	0.000143	CbGpPWpGaD
Imatinib—ABL1—Immune System—ERBB2—bile duct cancer	8.7e-05	0.000143	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—HRAS—bile duct cancer	8.53e-05	0.00014	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—EGFR—bile duct cancer	8.53e-05	0.00014	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—GNAS—bile duct cancer	8.43e-05	0.000138	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—HRAS—bile duct cancer	8.31e-05	0.000136	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—SMAD4—bile duct cancer	8.28e-05	0.000136	CbGpPWpGaD
Imatinib—PDGFRB—Disease—ERBB2—bile duct cancer	8.24e-05	0.000135	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—IDH1—bile duct cancer	8.23e-05	0.000135	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—HRAS—bile duct cancer	8.19e-05	0.000134	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—EGFR—bile duct cancer	8.19e-05	0.000134	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—IL6—bile duct cancer	8.16e-05	0.000134	CbGpPWpGaD
Imatinib—PDGFRB—Disease—PTGS2—bile duct cancer	8.06e-05	0.000132	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—KRAS—bile duct cancer	8.05e-05	0.000132	CbGpPWpGaD
Imatinib—KIT—Immune System—NRAS—bile duct cancer	7.96e-05	0.00013	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—IL6—bile duct cancer	7.96e-05	0.00013	CbGpPWpGaD
Imatinib—LCK—Hemostasis—TP53—bile duct cancer	7.95e-05	0.00013	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—MMP9—bile duct cancer	7.92e-05	0.00013	CbGpPWpGaD
Imatinib—ALB—Metabolism—SLC5A5—bile duct cancer	7.76e-05	0.000127	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—KRAS—bile duct cancer	7.73e-05	0.000127	CbGpPWpGaD
Imatinib—LCK—Hemostasis—HRAS—bile duct cancer	7.6e-05	0.000125	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—NRAS—bile duct cancer	7.54e-05	0.000124	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—IDH2—bile duct cancer	7.38e-05	0.000121	CbGpPWpGaD
Imatinib—KIT—Disease—NRAS—bile duct cancer	7.35e-05	0.00012	CbGpPWpGaD
Imatinib—ALB—Metabolism of lipids and lipoproteins—PTGS2—bile duct cancer	7.27e-05	0.000119	CbGpPWpGaD
Imatinib—KIT—Immune System—EGFR—bile duct cancer	7.26e-05	0.000119	CbGpPWpGaD
Imatinib—LCK—Immune System—ERBB2—bile duct cancer	7.16e-05	0.000117	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—NRAS—bile duct cancer	7.03e-05	0.000115	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—GNAS—bile duct cancer	7e-05	0.000115	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—SLC5A5—bile duct cancer	6.96e-05	0.000114	CbGpPWpGaD
Imatinib—PDGFRA—Disease—NRAS—bile duct cancer	6.96e-05	0.000114	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—EGFR—bile duct cancer	6.87e-05	0.000113	CbGpPWpGaD
Imatinib—KIT—Immune System—KRAS—bile duct cancer	6.85e-05	0.000112	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—HRAS—bile duct cancer	6.85e-05	0.000112	CbGpPWpGaD
Imatinib—KIT—Disease—TGFB1—bile duct cancer	6.83e-05	0.000112	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—SLC5A5—bile duct cancer	6.8e-05	0.000111	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—NRAS—bile duct cancer	6.79e-05	0.000111	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—ERBB2—bile duct cancer	6.77e-05	0.000111	CbGpPWpGaD
Imatinib—KIT—Disease—EGFR—bile duct cancer	6.7e-05	0.00011	CbGpPWpGaD
Imatinib—ABL1—Immune System—NRAS—bile duct cancer	6.62e-05	0.000108	CbGpPWpGaD
Imatinib—LCK—Disease—ERBB2—bile duct cancer	6.61e-05	0.000108	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—HRAS—bile duct cancer	6.57e-05	0.000108	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—IL6—bile duct cancer	6.55e-05	0.000107	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—TGFB1—bile duct cancer	6.53e-05	0.000107	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bile duct cancer	6.53e-05	0.000107	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—KRAS—bile duct cancer	6.49e-05	0.000106	CbGpPWpGaD
Imatinib—PDGFRA—Disease—TGFB1—bile duct cancer	6.47e-05	0.000106	CbGpPWpGaD
Imatinib—LCK—Disease—PTGS2—bile duct cancer	6.47e-05	0.000106	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—ERBB2—bile duct cancer	6.41e-05	0.000105	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—SLC5A5—bile duct cancer	6.41e-05	0.000105	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—EGFR—bile duct cancer	6.4e-05	0.000105	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—SLC5A5—bile duct cancer	6.35e-05	0.000104	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—IDH1—bile duct cancer	6.35e-05	0.000104	CbGpPWpGaD
Imatinib—PDGFRA—Disease—EGFR—bile duct cancer	6.34e-05	0.000104	CbGpPWpGaD
Imatinib—KIT—Disease—KRAS—bile duct cancer	6.33e-05	0.000104	CbGpPWpGaD
Imatinib—PDGFRB—Disease—NRAS—bile duct cancer	6.27e-05	0.000103	CbGpPWpGaD
Imatinib—ALB—Hemostasis—NRAS—bile duct cancer	6.21e-05	0.000102	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—EGFR—bile duct cancer	6.19e-05	0.000101	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—KRAS—bile duct cancer	6.05e-05	9.91e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—EGFR—bile duct cancer	6.03e-05	9.88e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—GNAS—bile duct cancer	6.03e-05	9.88e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—KRAS—bile duct cancer	5.99e-05	9.81e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bile duct cancer	5.95e-05	9.75e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—KRAS—bile duct cancer	5.85e-05	9.58e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—TGFB1—bile duct cancer	5.83e-05	9.55e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—HRAS—bile duct cancer	5.83e-05	9.55e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—MMP9—bile duct cancer	5.81e-05	9.51e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—TGFB1—bile duct cancer	5.77e-05	9.46e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—ERBB2—bile duct cancer	5.77e-05	9.46e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—EGFR—bile duct cancer	5.71e-05	9.36e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—KRAS—bile duct cancer	5.7e-05	9.33e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—IL6—bile duct cancer	5.58e-05	9.14e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—HRAS—bile duct cancer	5.51e-05	9.04e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—MMP9—bile duct cancer	5.5e-05	9e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—NRAS—bile duct cancer	5.45e-05	8.93e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—SLC5A5—bile duct cancer	5.43e-05	8.89e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—GNAS—bile duct cancer	5.41e-05	8.87e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—KRAS—bile duct cancer	5.4e-05	8.84e-05	CbGpPWpGaD
Imatinib—KIT—Disease—HRAS—bile duct cancer	5.38e-05	8.81e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—TP53—bile duct cancer	5.38e-05	8.81e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—KRAS—bile duct cancer	5.35e-05	8.76e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—GNAS—bile duct cancer	5.28e-05	8.65e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—IL6—bile duct cancer	5.28e-05	8.65e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—PTGS2—bile duct cancer	5.25e-05	8.6e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—PTGS2—bile duct cancer	5.2e-05	8.52e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—PTGS2—bile duct cancer	5.19e-05	8.51e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—NRAS—bile duct cancer	5.15e-05	8.44e-05	CbGpPWpGaD
Imatinib—KIT—Disease—IL6—bile duct cancer	5.15e-05	8.44e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—HRAS—bile duct cancer	5.14e-05	8.42e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—HRAS—bile duct cancer	5.09e-05	8.34e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bile duct cancer	5.09e-05	8.33e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—PTGS2—bile duct cancer	5.04e-05	8.26e-05	CbGpPWpGaD
Imatinib—LCK—Disease—NRAS—bile duct cancer	5.03e-05	8.24e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—GNAS—bile duct cancer	4.98e-05	8.16e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—HRAS—bile duct cancer	4.97e-05	8.14e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—EGFR—bile duct cancer	4.97e-05	8.14e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MMP9—bile duct cancer	4.95e-05	8.11e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—GNAS—bile duct cancer	4.93e-05	8.08e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—IL6—bile duct cancer	4.92e-05	8.06e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—NRAS—bile duct cancer	4.87e-05	7.99e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—IL6—bile duct cancer	4.87e-05	7.98e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—HRAS—bile duct cancer	4.84e-05	7.93e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—PTGS2—bile duct cancer	4.84e-05	7.93e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—TGFB1—bile duct cancer	4.78e-05	7.84e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—IL6—bile duct cancer	4.76e-05	7.79e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—TP53—bile duct cancer	4.75e-05	7.79e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—EGFR—bile duct cancer	4.69e-05	7.69e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—KRAS—bile duct cancer	4.69e-05	7.69e-05	CbGpPWpGaD
Imatinib—LCK—Disease—TGFB1—bile duct cancer	4.68e-05	7.66e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—IL6—bile duct cancer	4.63e-05	7.59e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—ERBB2—bile duct cancer	4.63e-05	7.59e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—HRAS—bile duct cancer	4.59e-05	7.52e-05	CbGpPWpGaD
Imatinib—LCK—Disease—EGFR—bile duct cancer	4.58e-05	7.51e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—HRAS—bile duct cancer	4.55e-05	7.45e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—TGFB1—bile duct cancer	4.53e-05	7.42e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—EGFR—bile duct cancer	4.44e-05	7.28e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—KRAS—bile duct cancer	4.43e-05	7.26e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—NRAS—bile duct cancer	4.39e-05	7.19e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—IL6—bile duct cancer	4.39e-05	7.19e-05	CbGpPWpGaD
Imatinib—LCK—Disease—KRAS—bile duct cancer	4.33e-05	7.1e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—GNAS—bile duct cancer	4.22e-05	6.91e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—KRAS—bile duct cancer	4.19e-05	6.87e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—SLC5A5—bile duct cancer	4.19e-05	6.86e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—TGFB1—bile duct cancer	4.08e-05	6.68e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—EGFR—bile duct cancer	4e-05	6.55e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—HRAS—bile duct cancer	3.99e-05	6.53e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MMP9—bile duct cancer	3.97e-05	6.51e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—TP53—bile duct cancer	3.94e-05	6.45e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—IL6—bile duct cancer	3.82e-05	6.25e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—KRAS—bile duct cancer	3.78e-05	6.19e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—HRAS—bile duct cancer	3.77e-05	6.17e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PTGS2—bile duct cancer	3.76e-05	6.16e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—TP53—bile duct cancer	3.73e-05	6.11e-05	CbGpPWpGaD
Imatinib—LCK—Disease—HRAS—bile duct cancer	3.68e-05	6.03e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—IL6—bile duct cancer	3.61e-05	5.91e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—HRAS—bile duct cancer	3.57e-05	5.84e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—NRAS—bile duct cancer	3.52e-05	5.77e-05	CbGpPWpGaD
Imatinib—LCK—Disease—IL6—bile duct cancer	3.52e-05	5.77e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—IL6—bile duct cancer	3.41e-05	5.59e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—TP53—bile duct cancer	3.36e-05	5.5e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—TGFB1—bile duct cancer	3.27e-05	5.36e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GNAS—bile duct cancer	3.25e-05	5.33e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—PTGS2—bile duct cancer	3.24e-05	5.3e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—HRAS—bile duct cancer	3.21e-05	5.26e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—EGFR—bile duct cancer	3.21e-05	5.26e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—IL6—bile duct cancer	3.07e-05	5.04e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—KRAS—bile duct cancer	3.03e-05	4.97e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PTGS2—bile duct cancer	2.91e-05	4.76e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PTGS2—bile duct cancer	2.84e-05	4.65e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—TP53—bile duct cancer	2.7e-05	4.42e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PTGS2—bile duct cancer	2.67e-05	4.38e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PTGS2—bile duct cancer	2.65e-05	4.34e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—HRAS—bile duct cancer	2.58e-05	4.22e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—IL6—bile duct cancer	2.47e-05	4.04e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PTGS2—bile duct cancer	2.26e-05	3.71e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PTGS2—bile duct cancer	1.75e-05	2.86e-05	CbGpPWpGaD
